ArticleFrontiers in immunology2025
Prognostic model construction and immune microenvironment analysis of pyroptosis-related genes in hepatocellular carcinoma based on single-cell RNA sequencing.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decoding the molecular mechanisms of pyroptosis and its therapeutic development prospects.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) prognosis continues to be challenging due to tumor heterogeneity and dynamic immunosuppressive microenvironments. Although pyroptosis plays a critical role in tumor-immune interactions, its prognostic significance in HCC at single-cell resolution has not been systematically investigated. Methods: We analyzed a publicly available single-cell RNA sequencing (scRNA-seq) data from 10 HCC tumors and paired adjacent tissue samples (60,496 cells) to elucidate pyroptosis-related gene (PRG) profiles. Differential expression and functional pathway analyses revealed PRG expression dynamics across cell subtypes. A LASSO-Cox prognostic model was developed using data from the liver hepatocellular carcinoma (LIHC) cohort of The Cancer Genome Atlas (TCGA) (n=365); the model was externally validated with International Cancer Genome Consortium (ICGC) datasets (n=231). Biological validation comprised reverse transcription quantitative polymerase chain reaction (RT-PCR) in HCC cell lines and immunohistochemical analysis of clinical specimens. Results: The scRNA-seq atlas identified 10 cellular clusters with enriched expression of 29 PRGs, primarily in natural killer cells, T lymphocytes, monocytes, and macrophages. The prognostic model developed in this study stratified patients into high-risk and low-risk categories based on eight significant genes, achieving area under the curve (AUC) values of 0.73, 0.65, and 0.69 for overall survival at one-year, two-year, and three-year intervals, respectively. Furthermore, external validation using data from the ICGC confirmed the prognostic model's discriminative ability. Notably, high-risk patients demonstrated enhanced sensitivity to immunotherapy, as indicated by decreased tumor immune dysfunction and exclusion (TIDE) scores and increased expression of the immune checkpoints PD-1 and CTLA4. Conclusions: This study established a scRNA-seq-derived prognostic model based on PRGs, which offers insights into HCC immune landscape remodeling. The risk score and nomogram integrate tumor stages and pyroptosis-associated signatures, providing a clinical tool for personalized prognosis and therapeutic targeting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.